PHIO PHARMACEUTICALS CORP.
Income Statement
| Line Item | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | Dec 2019 | Sep 2019 | Jun 2019 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $21.0K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $463.0K | $1.3M | $779.0K | $1.2M | $1.0M | $1.0M | $1.1M | $1.1M |
| SG&A Expense | $2.0M | $1.1M | $890.0K | $1.1M | $1.6M | $1.1M | $913.0K | $1.1M |
| Operating Income | $-2.5M | $-2.3M | $-1.7M | $-2.4M | $-2.7M | $-2.1M | $-2.1M | $-2.1M |
| Operating Margin | — | — | — | — | — | — | — | -10,219.0% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-2.5M | $-2.3M | $-1.7M | $-2.4M | $-2.7M | $-2.1M | $-2.0M | $-2.1M |
| Net Margin | — | — | — | — | — | — | — | -10,090.5% |
| EPS (Basic) | $0.01 | $-0.02 | $-0.01 | $-0.06 | $-0.19 | $-0.19 | $-0.19 | $-0.24 |
| EPS (Diluted) | $0.01 | $-0.02 | $-0.01 | $-0.06 | $-0.19 | $-0.19 | $-0.19 | $-0.24 |
| Shares Outstanding (Basic) | 138.7M | 138.7M | 138.7M | 68.8M | 16.1M | 615.7M | 602.2M | 561.3M |
| Shares Outstanding (Diluted) | 138.7M | 138.7M | 138.7M | 68.8M | 16.1M | 615.7M | 602.2M | 561.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |